4-(3-Methylphenyl)benzoyl chloride | 193153-29-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-Methylphenyl)benzoyl chloride
• CAS: 193153-29-6
• 化学式: C₁₄H₁₁ClO
• 分子量: 230.694
• InChiKey: OHGWBBZZNQVOGE-UHFFFAOYSA-N

物化性质

• 沸点：
  344.1±21.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(3-Methylphenyl)benzoyl chloride 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 sodium hydroxide 、 molecular sieve 、 硫化氢 、 ammonium acetate 、 三乙胺 、 碘甲烷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.67h， 生成 methyl (E,2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(3-methylphenyl)benzoyl]amino]-5-phenylpent-4-enoate
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y
• 作为产物：
  描述：

  3’-甲基联苯-4-甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 4-(3-Methylphenyl)benzoyl chloride
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y

文献信息

• Benzoheterocyclic derivatives
  申请人：Otsuka Pharmaceuticals Co., Ltd.

  公开号：US06335327B1

  公开（公告）日：2002-01-01

  A benzoheterocyclic derivative of the following formula [1]: and pharmaceutically acceptable salts thereof, which show excellent anti-vasopressin activity, vasopressin agonistic activity and oxytocin antagonistic activity, and are useful as a vasopressin antagonist, vasopressin agonist or oxytocin antagonist.

  以下是该句子的中文翻译： 一种苯并杂环衍生物，其化学式如下： 及其药用盐，表现出优异的抗加压素活性、加压素激动活性和催产素拮抗活性，可用作加压素拮抗剂、加压素激动剂或催产素拮抗剂。
• [EN] SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES<br/>[FR] N-[(AMINOIMINOMETHYLE OU AMINOMETHYLE)PHENYLE]PROPYLAMIDES A SUBSTITUTION
  申请人：RHONE-POULENC RORER PHARMACEUTICALS INC.

  公开号：WO1997024118A1

  公开（公告）日：1997-07-10

  (EN) The compounds according to the invention are substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides of formula (I) herein which exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), methods for their preparation and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.(FR) Composés constitués par des N-[(aminoiminométhyle ou aminométhyle)phényle]propylamides à substitution de la formule (I) exerçant une activité utile sur le plan pharmacologique et de ce fait incorporés dans des compositions pharmaceutiques pour le traitement de patients souffrants de certains troubles pathologiques. Ces composés sont plus spécialement des inhibiteurs du facteur Xa. L'invention porte sur des composés de la formule (I), des compositions contenant des composés de la formule (I), des méthodes de préparation et d'utilisation de ces composés pour le traitement d'un patient souffrant d'états pouvant être améliorés par l'administration d'un inhibiteur du facteur Xa.

  本发明涉及一种具有有用药理活性的取代N-[(氨基亚甲基或氨基甲基)苯基]丙基酰胺化合物，其化学式为(I)，因此被纳入制药组合物中并用于治疗患有某些医学疾病的患者。更具体地说，它们是凝血因子Xa抑制剂。本发明涉及化合物(I)、含有化合物(I)的组合物、其制备方法及其用途，用于治疗患有或受到可通过凝血因子Xa抑制剂的给药而改善的疾病的患者。
• [EN] SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES<br/>[FR] N-[AMINOIMINOMETHYL OU AMINOMETHYL)PHENYL]PROPYLAMIDES SUBSTITUES
  申请人：RHÔNE-POULENC RORER PHARMACEUTICALS INC.

  公开号：WO1999000356A1

  公开（公告）日：1999-01-07

  (EN) This invention relates to compounds of formula (I) which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.(FR) L'invention se rapporte à des composés de formule (I), qui inhibent le facteur Xa, à des compositions pharmaceutiques contenant lesdits composés et à l'utilisation desdits composés pour le traitement de patients présentant des pathologies pouvant être atténuées par l'administration d'un inhibiteur du facteur Xa.

  这项发明涉及到化合物公式（I），该化合物可以抑制Factor Xa，以及包含该化合物的药物组合物，以及使用该化合物治疗患有可以通过Factor Xa抑制剂治疗的疾病的患者。
• Biphenylcarboxamide derivatives as antagonists of platelet-activating factor
  作者：Jefferson W. Tilley、John W. Clader、Sonja Zawoiski、Maria Wirkus、Ronald A. LeMahieu、Margaret O'Donnell、Herman Crowley、Ann F. Welton

  DOI：10.1021/jm00128a025

  日期：1989.8

  A series of N-[4-(3-pyridinyl)butyl]-1,1'-biphenyl-4-carboxamides was prepared, and the compounds were evaluated for platelet-activating factor (PAF) antagonist activity in a binding assay employing washed, whole dog platelets and in vivo for their ability to inhibit PAF-induced bronchoconstriction in the guinea pig. The inclusion of a methyl group in the R configuration on the side-chain carbon adjacent to the carboxamide nitrogen atom of these derivatives resulted in a marked enhancement of potency in the binding assay for compounds unsubstituted in the biphenyl 2-position and, more importantly, in improved oral bioavailability. Previous work with related pyrido[2,1-b]-quinazoline-8-carboxamides suggests that the presence of such an alkyl group improves bioavailability by rendering the resulting compounds resistant to degradation by liver amidases. The most interesting compounds to emerge from this work are (R)-2-bromo-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]-1,1'-bi phe nyl- 4-carboxamide (33) and (R)-2-butyl-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]- 1,1'-biphenyl-4-carboxamide (40) each of which inhibits PAF-induced bronchoconstriction in the guinea pig by greater than 55%. 6 h after an oral dose of 50 mg/kg.
• SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES
  申请人：RHONE-POULENC RORER PHARMACEUTICALS, INC.

  公开号：EP0906094A1

  公开（公告）日：1999-04-07